Helix BioMedix Inc. (OTCMKTS:HXBM – Get Free Report) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 204 shares, a growth of 240.0% from the August 15th total of 60 shares. Based on an average daily trading volume, of 280 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the shares of the company are short sold.
Helix BioMedix Trading Up 69.0%
Helix BioMedix stock traded up $2.45 during midday trading on Friday, hitting $6.00. The stock had a trading volume of 400 shares, compared to its average volume of 302. Helix BioMedix has a 52-week low of $1.00 and a 52-week high of $6.50. The firm’s fifty day moving average is $2.30 and its two-hundred day moving average is $1.80.
About Helix BioMedix
Helix BioMedix, Inc (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.
Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates.
See Also
- Five stocks we like better than Helix BioMedix
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Helix BioMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioMedix and related companies with MarketBeat.com's FREE daily email newsletter.
